- Investing.com
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Metrics to compare | IPCA | Peers Peers - average of corresponding metrics from companies closely matching IPCA: MOREPENLAB, ZYDUSLIFE, LUPIN, JBCHEPHARM, EMCURE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPCAPeersSector |
---|---|---|---|---|
P/E Ratio | 46.3x | 29.9x | −0.6x | |
PEG Ratio | 1.32 | 0.94 | 0.00 | |
Price/Book | 5.2x | 5.3x | 2.6x | |
Price / LTM Sales | 3.9x | 4.7x | 3.3x | |
Upside (Analyst Target) | 9.6% | 12.8% | 39.1% | |
Fair Value Upside | Unlock | 0.2% | 5.4% | Unlock |